Affiliation:
1. Department of Intensive Care and Anaesthesia, Charing Cross Hospital, London W6 8RF, United Kingdom
Abstract
ABSTRACT
Many critically ill patients have increased extracellular fluid which might affect ceftazidime pharmacokinetics. We investigated the pharmacokinetics of ceftazidime in 15 adult intensive care patients receiving 2 g of ceftazidime intravenously three times a day. The ceftazidime mean (standard deviation) apparent volume of distribution and terminal-phase half-life were 56.91 (25.93) liters and 4.75 (1.85) h, respectively, significantly greater than values reported previously for healthy controls (
P
< 0.001). The mean ceftazidime clearance and area under the curve at steady state were not significantly different from those previously reported for controls. We conclude that ceftazidime pharmacokinetics in critically ill patients were altered by an increased volume of drug distribution and elevated elimination half-life.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference29 articles.
1. Assay of ceftazidime in biological fluids using high pressure liquid chromatography.;Ayrton J.;J. Antimicrob. Chemother.,1981
2. Archer
G. L.
Polk
R. E.
Treatment and prophylaxis of bacterial infections.
Harrison’s principles of internal medicine.
Isselbacher
K. J.
Braunwald
E.
Wilson
J. D.
Martin
J. B.
Fauci
A. S.
Kasper
D. L.
1994
McGraw Hill Inc
New York N.Y
3. Impact of dosage schedule of antibiotics on the treatment of serious infections.;Bakker Woudenberg I. A.;Intensive Care Med.,1990
4. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections
5. The pathogenesis of sepsis.;Bone R. C.;Ann. Intern. Med.,1991